孫銳
查看科室更多醫(yī)生
個人簡介
浙江大學(xué)附屬第一醫(yī)院特聘研究員,，碩士生導(dǎo)師,。致力于前列腺癌去勢抵抗耐藥分子機制研究,。目前已獲專利一項Assessing and treating prostate cancer,。主要研究成果發(fā)表于Molecular Cell, PNAS及 Cancer Research等國際期刊上。
專業(yè)擅長
腫瘤生物學(xué),，生物化學(xué)與分子生物學(xué)
研究方向
前列腺癌內(nèi)分泌治療耐藥的分子機制研究
成果獎項：（近五年主要成果及獎勵情況）
創(chuàng)新性的揭示了雄激素受體截斷體（AR-Vs）產(chǎn)生的具體的分子機制,，為前列腺癌去勢抵抗治療提供了研究基礎(chǔ)。
代表性論著：
1. Sun, R., Wei, T., Ding, D., Zhang, J., Chen, S., He, H. H., . . . Huang, H. (2022). CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer. Proc Natl Acad Sci U S A, 119(39), e2205509119. doi:10.1073/pnas.2205509119
2. Sun, R., Yan, B., Li, H., Ding, D., Wang, L., Pang, J., . . . Huang, H. (2023). Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis. Cancer Res, 83(19), 3192-3204. doi:10.1158/0008-5472.CAN-23-0285
3. Sun, R., Xie, H. Y., Qian, J. X., Huang, Y. N., Yang, F., Zhang, F. L., . . . Li, D. Q. (2018). FBXO22 Possesses Both Protumorigenic and Antimetastatic Roles in Breast Cancer Progression. Cancer Res, 78(18), 5274-5286. doi:10.1158/0008-5472.CAN-17-3647
4. Zhang, J.*, Wei, J.*, Sun, R.*, Sheng, H., Yin, K., Pan, Y., . . . Huang, H. (2023). A lncRNA from the FTO locus acts as a suppressor of the m(6)A writer complex and p53 tumor suppression signaling. Mol Cell, 83(15), 2692-2708 e2697. doi:10.1016/j.molcel.2023.06.024 (* Co-first author)
5. Yang, F.*, Sun, R.*, Hou, Z., Zhang, F. L., Xiao, Y., Yang, Y. S., . . . Li, D. Q. (2022). HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression. Clin Transl Med, 12(5), e825. doi:10.1002/ctm2.825 (* Co-first author)
6. Tang, B., Sun, R., Wang, D., Sheng, H., Wei, T., Wang, L., . . . Huang, H. (2021). ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. Proc Natl Acad Sci U S A, 118(8). doi:10.1073/pnas.2019052118
7. Huang, Z., Li, X., Tang, B., Li, H., Zhang, J., Sun, R., . . . Jia, Z. (2023). SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors. Cancer Res, 83(6), 875-889. doi:10.1158/0008-5472.CAN-22-0264
8. Zhang, F. L., Cao, J. L., Xie, H. Y., Sun, R., Yang, L. F., Shao, Z. M., & Li, D. Q. (2018). Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer. Cancer Res, 78(20), 5780-5792. doi:10.1158/0008-5472.CAN-17-1394
